Malignant Endometrial Neoplasm — Trials

Malignant Endometrial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,198 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 359
Recruiting: 203
Ph III recruiting: 21
Growth YoY: +3.8%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (112)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04906382	Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer	terminated	Early Phase 1	2	Floor Backes, MDOTHER	1	Feb 13, 2025	clinicaltrials
NCT03514121	FPA150 in Patients With Advanced Solid Tumors(FPA150-001)	terminated	Early Phase 1	95	Five Prime Therapeutics, Inc.INDUSTRY	2	Nov 22, 2024	clinicaltrials